Wed, 25 Oct 2006 3:30:00 PDT
SAN MATEO, CA -- (MARKET WIRE) -- 10/25/2006 -- SciClone Pharmaceuticals, Inc. (
To access the live audio webcast of the presentation, log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. A replay of the webcast will be available until November 27, 2006.
About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products, such as the DC Bead distribution rights, to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.
Corporate contact: Richard Waldron Chief Financial Officer SciClone Pharmaceuticals, Inc. 650-358-3437
A Stock Cloud is a tag cloud like display of stock ticker symbols. The larger the ticker symbol the more frequent that company distributes press releases.